Biodexa Pharmaceuticals Plc
BDRX
$7.51
-$0.26-3.35%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -19.45% | -24.45% | 84.40% | 83.83% | -1.99% |
| Gross Profit | 19.45% | 24.45% | -93.24% | -92.63% | -12.96% |
| SG&A Expenses | 23.81% | 16.12% | 144.74% | 143.98% | -10.53% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -128.74% | -126.97% | -- |
| Total Operating Expenses | 0.70% | -5.55% | 101.74% | 101.11% | -6.30% |
| Operating Income | -0.70% | 5.55% | -108.54% | -107.90% | -0.28% |
| Income Before Tax | -22.49% | -14.89% | 27.67% | 27.89% | 10.27% |
| Income Tax Expenses | -39.85% | -31.02% | -9.14% | -8.84% | 56.27% |
| Earnings from Continuing Operations | -21.84% | -14.27% | 28.91% | 29.13% | 6.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.84% | -14.27% | 28.91% | 29.13% | 6.56% |
| EBIT | -0.70% | 5.55% | -108.54% | -107.90% | -0.28% |
| EBITDA | -0.54% | 5.70% | -112.54% | -111.88% | -0.39% |
| EPS Basic | 84.18% | 85.16% | -- | -- | -- |
| Normalized Basic EPS | 84.10% | 85.08% | -- | -- | -- |
| EPS Diluted | 84.18% | 85.16% | -- | -- | -- |
| Normalized Diluted EPS | 84.10% | 85.08% | -- | -- | -- |
| Average Basic Shares Outstanding | 670.43% | 670.43% | -- | -- | -- |
| Average Diluted Shares Outstanding | -- | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |